| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
,
Departments of
*
Microbiology and Immunology and
Medicine, Division of Infectious Diseases, Albert Einstein College of Medicine, Bronx, NY 10461;
Uniformed Services University, Bethesda, MD 20892; and
Biosynexus, Inc., Rockville, MD 20853
Defined Abs to the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been shown to be protective against experimental cryptococcosis. This suggests that if a vaccine could induce similar Abs it might protect against infection. However, the potential use of a GXM-based vaccine has been limited by evidence that GXM is a poor immunogen that can induce nonprotective and deleterious, as well as protective, Abs, and that the nature of GXM oligosaccharide epitopes that can elicit a protective response is unknown. In this study, we investigated whether a peptide surrogate for a GXM epitope could induce an Ab response to GXM in mice. The immunogenicity of peptide-protein conjugates produced by linking a peptide mimetic of GXM, P13, to either BSA, P13-BSA, or tetanus toxoid, P13-tetanus toxoid, was examined in BALB/c and CBA/n mice that received four s.c. injections of the conjugates at 14- to 30-day intervals. All mice immunized with conjugate produced IgM and IgG to P13 and GXM. Challenge of conjugate-immunized mice with C. neoformans revealed longer survival and lower serum GXM levels than control mice. These results indicate that 1) P13 is a GXM mimotope and 2) that it induced a protective response against C. neoformans in mice. P13 is the first reported mimotope of a C. neoformans Ag. Therefore, the P13 conjugates are vaccine candidates for C. neoformans and their efficacy in this study suggests that peptide mimotopes selected by protective Abs deserve further consideration as vaccine candidates for encapsulated pathogens.
This article has been cited by other articles:
|
|
 |
|
  K. Datta, A. Lees, and L.-a. Pirofski Therapeutic Efficacy of a Conjugate Vaccine Containing a Peptide Mimotope of Cryptococcal Capsular Polysaccharide Glucuronoxylomannan Clin. Vaccine Immunol., August 1, 2008; 15(8): 1176 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Borrelli, R. B. Hossany, and B. M. Pinto Immunological Evidence for Functional Rather than Structural Mimicry by a Shigella flexneri Y Polysaccharide-Mimetic Peptide Clin. Vaccine Immunol., July 1, 2008; 15(7): 1106 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Dharmasena, D. A. Jewell, and R. K. Taylor Development of Peptide Mimics of a Protective Epitope of Vibrio cholerae Ogawa O-antigen and Investigation of the Structural Basis of Peptide Mimicry J. Biol. Chem., November 16, 2007; 282(46): 33805 - 33816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Jalali, L. Ng, N. Singh, and L.-a. Pirofski Antibody Response to Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan in Patients after Solid-Organ Transplantation. Clin. Vaccine Immunol., July 1, 2006; 13(7): 740 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Clement, A. Fortune, A. Phalipon, V. Marcel-Peyre, C. Simenel, A. Imberty, M. Delepierre, and L. A. Mulard Toward a Better Understanding of the Basis of the Molecular Mimicry of Polysaccharide Antigens by Peptides: THE EXAMPLE OF SHIGELLA FLEXNERI 5A J. Biol. Chem., January 27, 2006; 281(4): 2317 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Martinez and A. Casadevall Specific Antibody Can Prevent Fungal Biofilm Formation and This Effect Correlates with Protective Efficacy Infect. Immun., October 1, 2005; 73(10): 6350 - 6362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. K. Buchwald, A. Lees, M. Steinitz, and L.-a. Pirofski A Peptide Mimotope of Type 8 Pneumococcal Capsular Polysaccharide Induces a Protective Immune Response in Mice Infect. Immun., January 1, 2005; 73(1): 325 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Maitta, K. Datta, Q. Chang, R. X. Luo, B. Witover, K. Subramaniam, and L.-a. Pirofski Protective and Nonprotective Human Immunoglobulin M Monoclonal Antibodies to Cryptococcus neoformans Glucuronoxylomannan Manifest Different Specificities and Gene Use Profiles Infect. Immun., August 1, 2004; 72(8): 4810 - 4818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. McFadden and A. Casadevall Unexpected Diversity in the Fine Specificity of Monoclonal Antibodies That Use the Same V Region Gene to Glucuronoxylomannan of Cryptococcus neoformans J. Immunol., March 15, 2004; 172(6): 3670 - 3677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Maitta, K. Datta, A. Lees, S. S. Belouski, and L.-a. Pirofski Immunogenicity and Efficacy of Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice Infect. Immun., January 1, 2004; 72(1): 196 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. May, D. O. Beenhouwer, and M. D. Scharff Antibodies to Keyhole Limpet Hemocyanin Cross-React with an Epitope on the Polysaccharide Capsule of Cryptococcus neoformans and Other Carbohydrates: Implications for Vaccine Development J. Immunol., November 1, 2003; 171(9): 4905 - 4912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hou and X.-X. Gu Development of Peptide Mimotopes of Lipooligosaccharide from Nontypeable Haemophilus influenzae as Vaccine Candidates J. Immunol., April 15, 2003; 170(8): 4373 - 4379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Beenhouwer, R. J. May, P. Valadon, and M. D. Scharff High Affinity Mimotope of the Polysaccharide Capsule of Cryptococcus neoformans Identified from an Evolutionary Phage Peptide Library J. Immunol., December 15, 2002; 169(12): 6992 - 6999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Chang, Z. Zhong, A. Lees, M. Pekna, and L. Pirofski Structure-Function Relationships for Human Antibodies to Pneumococcal Capsular Polysaccharide from Transgenic Mice with Human Immunoglobulin Loci Infect. Immun., September 1, 2002; 70(9): 4977 - 4986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rivera, J. Mukherjee, L. M. Weiss, and A. Casadevall Antibody Efficacy in Murine Pulmonary Cryptococcus neoformans Infection: A Role for Nitric Oxide J. Immunol., April 1, 2002; 168(7): 3419 - 3427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Feldmesser, A. Mednick, and A. Casadevall Antibody-Mediated Protection in Murine Cryptococcus neoformans Infection Is Associated with Pleotrophic Effects on Cytokine and Leukocyte Responses Infect. Immun., March 1, 2002; 70(3): 1571 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Granoff, G. R. Moe, M. M. Giuliani, J. Adu-Bobie, L. Santini, B. Brunelli, F. Piccinetti, P. Zuno-Mitchell, S. S. Lee, P. Neri, et al. A Novel Mimetic Antigen Eliciting Protective Antibody to Neisseria meningitidis J. Immunol., December 1, 2001; 167(11): 6487 - 6496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cunto-Amesty, T. K. Dam, P. Luo, B. Monzavi-Karbassi, C. F. Brewer, T. C. Van Cott, and T. Kieber-Emmons Directing the Immune Response to Carbohydrate Antigens J. Biol. Chem., August 3, 2001; 276(32): 30490 - 30498. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
